HPTN 035
Status:Completed
Phase:IIb
Principal Investigator(s):
Objective:To test the safety and efficacy of BufferGel and PRO 2000.
Prevention Option(s):Microbicides
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionApply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Mode of DeliveryGel
ARMsExperimental
DescriptionApply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Mode of DeliveryGel
ARMsExperimental
Official Code:
NCT00074425
Trial Sponsors:
MTN, NIAID, NICHD, NIMH
Start Date
End Date
January 31, 2005
September 30, 2008
Enrollment:3,101
Age range:
18 Years ↔
any
Population:Cisgender Women